Exiqon
Home Search Contact Print
0 items in basket0
Sign In
 
 
Products Services Applications Resource Center Ordering About Exiqon Investor
microRNA Research
lncRNA Research
mRNA Research
DNA Research
Custom Oligos
Other Reagents
RNA Isolation
Microarray Analysis
Real-time PCR
Northern Blotting
In Situ Hybridization
Functional Analysis
RNA Preparation
Microarray analysis
Real-time PCR
In Situ Hybridization
Antisense
RNA Preparation
Microarray analysis
Real-time PCR
In Situ Hybridization
Antisense
SNP Detection
Microarray Analysis
In Situ Hybridization
LNA Phosphoramidites
A2 Quencher
RNA Isolation Services
microRNA Array Services
microRNA PCR Services
Sequencing Services
microRNA ISH Services
Custom Pharma Service
Isolation
Microarray Analysis
Northern Blotting
Real-time PCR
In Situ Hybridization
Functional Analysis
SNP Detection
RNA
microRNA
RNA
DNA
microRNA
microRNA
mRNA
microRNA
Other RNAs
DNA
microRNA
RNA
DNA
microRNA Resources
lncRNA Resources
mRNA Resources
Tech literature and Manuals
Technology Base
Oligo design tools
Exiqon E-talk
microRNA
Research Guide
microRNA reading rooms
Application Stories
Bioinformatics and data analysis
What are lncRNAs?
Application Stories
Bioinformatics
Oligo modifications
LNA™
AQ-link
Order microRNA products
Order custom oligos
Distributors
Global Service Providers
General Information
Contact
News
Company profile
History
Management
Board of Directors
Awards & Partnerships
Newsletter
Career
Sign up to Newsletter
Newsletter Back Issues
 
Exiqon Grant Program

The results are in for this year's Grant Program.



We had an overwhelming response to this year's grant program with many qualified applications worldwide. Many projects were of extremely high quality and deciding on which applications to accept was very difficult.

Ultimately, our review panel decided on awarding grants to the following projects:




Non-coding RNAs as biomarkers for cardiovascular disease

Dr. Lars Maegdefessel is an Assistant Professor of Medicine at the Karolinska Institute and University Hospital in Stockholm, Sweden. His research is focused on the therapeutic and biomarker potential of non-coding RNAs in cardiovascular disease. His team utilizes human biobank material for microRNA and lncRNA profiling studies. Results from these studies are extensively tested in experimental models, enabling his team to identify novel therapeutic strategies on a molecular basis to combat the burden of cardiovascular disease. His currently proposed project aims at identifying lncRNAs being crucial for atherosclerotic plaque vulnerability (in patients with carotid stenosis), as well as abdominal aortic aneurysm development.




MicroRNA mediated regression of infantile hemangioma by propanolol

Dr. Graham Michael Strub, M.D./Ph.D. is an Otolaryngology/Head and Neck Surgery resident at the University of Washington in Seattle. His research at the Seattle Children's Research Institute focuses on propanolol-mediated regression of infantile hemangioma, a common vascular tumor of infancy. The goal of this project is the identification of the propanolol-responsive miRNA sequences that are responsible for the aberrant angiogenesis present in hemangioma, as well as the development of miRNA screening tests to predict responsiveness to the drug propanolol.




Long non-coding RNAs: the white/brown fat switch in humans?

Dr. Søren Nielsen is a Post doctoral researcher at the Centre of Inflammation and Metabolism at Rigshospitalet in Denmark. His research focus is long non-coding RNAs (lncRNAs) and their role in brown adipogenesis in humans. Human brown fat is intensely studied due to its potential anti-diabetic properties. The aim of the proposed project is to investigate the function of five lncRNAs substantially expressed in white fat and barely detectable in brown fat cells. LncRNAs are potent regulators of gene expression through chromatin modifications and therefore possible determinants of brown versus white fat cell fate. Identifying a lncRNA that turn excess white fat into brown could provide a tool for counteracting obesity and its associated diseases.






Follow us on Facebook Follow us on Twitter Follow us on LinkedIn
GenPattern






Previous years' winners

See our grant recipients from previous years.

Read more

  Privacy   Sitemap   Legal